Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77.3M
-
Number of holders
-
129
-
Total 13F shares, excl. options
-
47.7M
-
Shares change
-
+13.2M
-
Total reported value, excl. options
-
$1.49B
-
Value change
-
+$454M
-
Put/Call ratio
-
0.68
-
Number of buys
-
80
-
Number of sells
-
-48
-
Price
-
$31.24
Significant Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q4 2021
173 filings reported holding XENE - Xenon Pharmaceuticals Inc. - Common Stock as of Q4 2021.
Xenon Pharmaceuticals Inc. - Common Stock (XENE) has 129 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 47.7M shares
of 77.3M outstanding shares and own 61.67% of the company stock.
Largest 10 shareholders include Avoro Capital Advisors LLC (4.99M shares), FMR LLC (3.91M shares), BVF INC/IL (3.29M shares), DRIEHAUS CAPITAL MANAGEMENT LLC (3.12M shares), Point72 Asset Management, L.P. (2.99M shares), PERCEPTIVE ADVISORS LLC (2.41M shares), Capital World Investors (2.27M shares), LORD, ABBETT & CO. LLC (1.8M shares), Polar Capital Holdings Plc (1.69M shares), and CITADEL ADVISORS LLC (1.29M shares).
This table shows the top 129 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.